Comparison Between Tumour Metabolism Derived from F-FDG PET/CT and Accurate Cytogenetic Stratification in Newly Diagnosed Multiple Myeloma Patients

Overview

Journal Quant Imaging Med Surg

Specialty Radiology

Date 2021 Oct 4

PMID 34603985

Citations 2

Authors

Yannick Silva

Jean-Marc Riedinger

Marie-Lorraine Chretien

Denis Caillot

Jill Corre

Kevin Guillen

Alexandre Cochet

Claire Tabouret-Viaud

Romaric Loffroy

Affiliations

Soon will be listed here.

Abstract

Background: F-fluorodeoxyglucose positron emission tomography integrated with computed tomography (F-FDG PET/CT) is a useful tool for baseline staging in newly diagnosed multiple myeloma (MM) but also for prognostic stratification. This monocentric retrospective study aimed at examining the relation between baseline tumour metabolism assessed by F-FDG PET/CT and linear predictor (LP) score, a new cytogenetic stratification score.

Methods: From March 2012 to March 2019, 57 patients with newly diagnosed MM addressed to our institution for baseline F-FDG PET/CT were included. LP score was determined on systematic iliac crest bone marrow samples. Obtained on CD138-sorted bone marrow plasma cells, this recent composite cytogenetic stratification is a 6-marker based weighted score using fluorescence in situ hybridization (FISH) ± single nucleotide polymorphism (SNP) arrays. We compared quantitative metabolic parameters and LP score using a Kruskal-Wallis test and visual suspicion of diffuse bone marrow involvement (DBI; based on hepatic background as threshold of positivity) and cytogenetic data using a Chi-squared test.

Results: The distribution of total metabolic tumour volume (TMTV) and total lesion glycolysis (TLG) values among the three LP score categories was almost stochastic, with no significant association (P=0.70). Additionally, no significant association between TMTV/TLG and any of the six cytogenetic abnormalities included in LP score calculation. A significant association was found between visual high suspicion of DBI and LP score (P=0.036), and between this visual parameter and the presence of 1q gain (P=0.049).

Conclusions: There is no significant association between quantitative metabolic parameters assessed with F-FDG PET/CT and LP score in patients with newly diagnosed MM, suggesting a potential complementarity of these biomarkers for prognostic stratification. A significant association was found between high visual suspicion of DBI and LP score.

Citing Articles

Case report: Thoracic and lumbar plasma cell myeloma mimicking hemangiomas on MRI and F-FDG PET/CT.

Hu X, Xiong W, Li S, Li X, Cai J, Wang P Front Med (Lausanne). 2022; 9:967531.

PMID: 35991641 PMC: 9386064. DOI: 10.3389/fmed.2022.967531.

Identifying F-FDG PET-metabolic radiomic signature for lung adenocarcinoma prognosis via the leveraging of prognostic transcriptomic module.

Li J, Liu Y, Dong W, Zhou Y, Wu J, Luan K Quant Imaging Med Surg. 2022; 12(3):1893-1908.

PMID: 35284267 PMC: 8899934. DOI: 10.21037/qims-21-706.

References

Stolzenburg A, Luckerath K, Samnick S, Speer M, Kneer K, Schmid J . Prognostic value of [F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. Eur J Nucl Med Mol Imaging. 2018; 45(10):1694-1704. DOI: 10.1007/s00259-018-3997-0. View

Mulligan M, Chirindel A, Karchevsky M . Characterizing and predicting pathologic spine fractures in myeloma patients with FDG PET/CT and MR imaging. Cancer Invest. 2011; 29(5):370-6. DOI: 10.3109/07357907.2011.584589. View

Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S . Role of F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017; 18(4):e206-e217. DOI: 10.1016/S1470-2045(17)30189-4. View

Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O . Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014; 41(9):1735-43. DOI: 10.1007/s00259-014-2783-x. View

Pawlyn C, Melchor L, Murison A, Wardell C, Brioli A, Boyle E . Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood. 2014; 125(5):831-40. PMC: 4327151. DOI: 10.1182/blood-2014-07-584268. View

McDonald J, Kessler M, Gardner M, Buros A, Ntambi J, Waheed S . Assessment of Total Lesion Glycolysis by F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clin Cancer Res. 2016; 23(8):1981-1987. PMC: 5777601. DOI: 10.1158/1078-0432.CCR-16-0235. View

Spinnato P, Bazzocchi A, Brioli A, Nanni C, Zamagni E, Albisinni U . Contrast enhanced MRI and ¹⁸F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease. Eur J Radiol. 2012; 81(12):4013-8. DOI: 10.1016/j.ejrad.2012.06.028. View

Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M . Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2017; 45(5):712-719. DOI: 10.1007/s00259-017-3909-8. View

Kanoun S, Tal I, Berriolo-Riedinger A, Rossi C, Riedinger J, Vrigneaud J . Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma. PLoS One. 2015; 10(10):e0140830. PMC: 4608733. DOI: 10.1371/journal.pone.0140830. View

10.

Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A . Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011; 118(23):5989-95. DOI: 10.1182/blood-2011-06-361386. View

11.

Usmani S, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N . Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013; 121(10):1819-23. PMC: 3591801. DOI: 10.1182/blood-2012-08-451690. View

12.

Batsukh K, Lee S, Min G, Park S, Jeon Y, Yoon J . Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma. Immune Netw. 2017; 17(4):250-260. PMC: 5577302. DOI: 10.4110/in.2017.17.4.250. View

13.

Durie B . The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006; 42(11):1539-43. DOI: 10.1016/j.ejca.2005.11.037. View

14.

Fouquet G, Guidez S, Herbaux C, Van de Wyngaert Z, Bonnet S, Beauvais D . Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Clin Cancer Res. 2014; 20(12):3254-60. DOI: 10.1158/1078-0432.CCR-13-2910. View

15.

Kazandjian D . Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2017; 43(6):676-681. PMC: 5283695. DOI: 10.1053/j.seminoncol.2016.11.004. View

16.

Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L . Prospective Evaluation of Magnetic Resonance Imaging and [F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009.... J Clin Oncol. 2017; 35(25):2911-2918. PMC: 5578392. DOI: 10.1200/JCO.2017.72.2975. View

17.

Hebraud B, Magrangeas F, Cleynen A, Lauwers-Cances V, Chretien M, Hulin C . Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood. 2015; 125(13):2095-100. PMC: 4375107. DOI: 10.1182/blood-2014-07-587964. View

18.

Hathi D, DeLassus E, Achilefu S, McConathy J, Shokeen M . Imaging Melphalan Therapy Response in Preclinical Extramedullary Multiple Myeloma with F-FDOPA and F-FDG PET. J Nucl Med. 2018; 59(10):1551-1557. PMC: 6167538. DOI: 10.2967/jnumed.118.208744. View

19.

Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G . Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia. 2013; 28(3):675-9. PMC: 6140327. DOI: 10.1038/leu.2013.225. View

20.

Zamagni E, Nanni C, Gay F, Pezzi A, Patriarca F, Bello M . 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia. 2015; 30(2):417-22. DOI: 10.1038/leu.2015.291. View